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Mammalian Fe-S cluster assemblyIron–sulfur (Fe–S) clusters are ancient, ubiquitous cofactors composed of iron and inorganic sulfur. The combina-
tion of the chemical reactivity of iron and sulfur, together with many variations of cluster composition, oxidation
states and protein environments, enables Fe–S clusters to participate in numerous biological processes. Fe–S clus-
ters are essential to redox catalysis in nitrogen ﬁxation, mitochondrial respiration and photosynthesis, to regula-
tory sensing in key metabolic pathways (i.e. cellular iron homeostasis and oxidative stress response), and to the
replication and maintenance of the nuclear genome.
Fe–S cluster biogenesis is a multistep process that involves a complex sequence of catalyzed protein–protein in-
teractions and coupled conformational changes between the components of several dedicated multimeric com-
plexes. Intensive studies of the assembly process have clariﬁed key points in the biogenesis of Fe–S proteins.
However several critical questions still remain, such as: what is the role of frataxin? Why do some defects of
Fe–S cluster biogenesis cause mitochondrial iron overload? How are speciﬁc Fe–S recipient proteins recognized
in the process of Fe–S transfer?
This review focuses on the basic steps of Fe–S cluster biogenesis, drawing attention to recent advances achieved
on the identiﬁcation of molecular features that guide selection of speciﬁc subsets of nascent Fe–S recipients by
the cochaperone HSC20. Additionally, it outlines the distinctive phenotypes of human diseases due tomutations
in the components of the basic pathway. This article is part of a Special Issue entitled: Fe/S proteins: Analysis,
structure, function, biogenesis and diseases.
Published by Elsevier B.V.1. Introduction
First identiﬁed around 1960 in studies of photosynthetic organisms
[1] and nitrogen-ﬁxing bacteria [2], and later in succinate dehydroge-
nase enzymes of porcine and bovine origins [3,4], Fe–S clusters are pros-
thetic groups common to themost ancient components of livingmatter.
Ferredoxins were among the ﬁrst representatives of the Fe–S
metalloprotein family to be identiﬁed and have their iron content and
their redox properties characterized [3]. By the mid-1960s, additional
Fe–S proteins of bacterial origin were already the subject of intense
studies, and they were shown to contain complexes of iron and acidic-
labile sulﬁde in the form of two- and four-iron clusters [3]. It quickly be-
came evident that Fe–S species of nuclearities 1, 2, and 4 could be syn-
thesized in aprotic anaerobic solvents in a cell-free system, and these
synthetic Fe–S clusters served as accurate analogs of the protein-
bound centers [5,6]. The widespread occurrence of Fe–S proteins and
their particular abundance in hyper-thermophilic archeabacteria livingteins: Analysis, structure, func-at around 100 °C in deep oceanic faults support the notion that Fe–S
centers were already present as inorganic metal compounds in the an-
aerobic atmosphere of earth, more than 4.2 billion years ago [7], and
that they might have been incorporated into early metabolic pathways
by primitive organisms [8]. An important role for Fe–S clusters in the or-
igin of life explains the high level of conservation of Fe–S proteins and of
the Fe–S biogenesis machinery among all kingdoms of life: moreover,
molecular mechanisms aimed at protecting and enshrouding Fe–S cen-
ters during most of the biogenesis and transfer processes likely evolved
once plants oxygenated the atmosphere and exposed Fe–S clusters to
potential oxidative damage [9]. The vulnerability of Fe–S clusters to ox-
idation appears to be their Achilles' heel, yet it is also the property that
enables them to function as redox active centers for electron transfer in
the respiratory chain complexes I to III or in photosystem I of photosyn-
thetic organisms. The bacterial regulatory proteins fumarate and nitrate
reduction protein, FNR, and IscR function as O2 sensors by virtue of their
oxygen-sensitive Fe–S clusters [10,11]. Importantly, Fe–S proteins play
crucial roles in nitrogenﬁxation (in nitrogenases) aswell as in reduction
of protons into hydrogen (in hydrogenases).
Due to their structural versatility, Fe–S proteins are also involved in
numerous other functions. A solvent exposed Fe–S cluster directly par-
ticipates in substrate binding and acid–base catalysis in a family of
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The cytosolic isoform of aconitase is a bifunctional enzyme (iron regula-
tory protein 1, IRP1/cytosolic aconitase, ACO1), endowed with a crucial
function in regulation of cytosolic iron homeostasis [12–14]. Several
nucleic acid processing enzymes, such as glycosylases, helicases and
primases require Fe–S clusters for their function [15]. Proteins involved
in DNA replication have Fe–S centers that are essential for replisome
assembly and stability [16]. Moreover, Fe–S clusters are present in
DNA repair enzymes (Fanconi anemia group J protein, FANCJ), and in
the transcription-coupled nucleotide excision repair (Xeroderma
pigmentosum group D protein, XPD) [16,17]. The ﬁrst Fe–S protein
identiﬁed as essential for eukaryotic cell viabilitywas themultifunction-
al ABC-family protein, termed Rli1 in the yeast model, or ABCE1 in
humans and other organisms [18,19]. Rli1 has roles in ribosome biogen-
esis and maturation [18,19], translation initiation [20,21], translation
termination [22,23], and ribosome recycling [23]. Integrity of the N-
terminal [Fe4–S4]-cluster domain of Rli1p is crucial for its function in
protein synthesis [24]. S-adenosyl-L-methionine (SAM)-dependent en-
zymes, such as lipoic acid synthase (LIAS), which is involved in the en-
dogenous synthesis of lipoate [25], and biotin synthase, which is
involved in biotin synthesis in lower organisms [26], are also Fe–S
proteins.
The remarkable structural versatility of Fe–S clusters constitutes the
basis for their widespread occurrence andmultiplicity of function. Most
frequently, Fe–S proteins contain the rhomboid [Fe2–S2], the cuboidal
[Fe3–S4], and the cubane [Fe4–S4] clusters [6]: howevermore complicat-
ed forms have been characterized that also harbor other metal ions [6].
Fe–S clusters are typically ligated by cysteine residues of the polypep-
tide chain, but other amino acids, such as serine, arginine, and histidine,
may also function as ligands. For instance two cysteines and two histi-
dines coordinate the [Fe2–S2] cluster of the Rieske protein of respiratory
chain complex III.
Although as early as the 1970s it was known that Fe–S clusters could
be synthesized from inorganic components in vitro under strictly anaer-
obic conditions [6], in the late 1980s the pioneering work by Dean and
co-workers in bacteria revealed that biogenesis of Fe–S clusters in vivo
is amultistep process that involves a complicated sequence of catalyzed
protein–protein interactions and coupled conformational changes be-
tween the components of several dedicated multimeric complexes
[27,28]. In eukaryotes the scenario is complicated by the requirement
for Fe–S proteins in distinct subcellular compartments, including mito-
chondria, plastids, cytosol and nuclei [29–31]. In mammalian cells, Fe–
S clusters are assembled upon the scaffold protein ISCU, through a coor-
dinated set of reactions accomplished by a core complex composed of a
cysteine desulfurase, NFS1, its binding partner, ISD11 (LYRM4), and an
iron donor or allosteric effector, frataxin [30]. NFS1 abstracts sulfur
from free cysteine, and the subsequent reduction of sulfane sulfur (S0)
to sulﬁde (S2−) likely involves the concerted action of ferredoxin
(FDX1 and FDX2 in humans [32]) and ferredoxin reductase (FDXR),
which have been shown to provide electrons in prokaryotes [33]. After
a nascent cluster forms upon ISCU, it has to be transferred to recipient
proteins. A specialized chaperone/cochaperone system has evolved in
bacteria (HscA/HscB) and in certain fungi (Ssq1/Jac1), whereas most
eukaryotes employ the multifunctional mitochondrial HSP70
(mtHSP70) together with a specialized cochaperone, the orthologue of
HscB/Jac1 [34,35].
Intensive studies of the assembly process have clariﬁed key points in
the biogenesis of Fe–S proteins. However several critical questions still
remain unanswered, including elucidating the role of frataxin, and iden-
tifying themolecularmechanisms that guide delivery of Fe–S clusters to
speciﬁc recipients. Interestingly, studies of several newly described syn-
dromes caused bymutations in NFU1 or BOLA3, and IBA57 (see Table 1)
suggest that transfer of Fe–S clusters downstream of the ISCU–chaper-
one–cochaperone complex depends on selective pathways, which un-
derscores our lack of knowledge about how discrete subsets of Fe–S
proteins are targeted for acquisition of their prosthetic groups [30,36].In this review, we will focus ﬁrst on the basic steps of Fe–S cluster
biogenesis in mammalian cells. We will then discuss recent advances
achieved in the identiﬁcation of molecular features that guide selection
of speciﬁc Fe–S recipient proteins by the cochaperoneHSC20 [37]. Final-
ly, we will outline the distinctive phenotypes of several human diseases
that result from mutations in the components of the basic pathway.
2. Fe–S cluster biogenesis: the assembly step
Three distinctive systems, which are required for intracellular for-
mation of Fe–S clusters, have been identiﬁed in bacteria, and they are
encoded by the nif, isc and suf operons (for a review, see [38]). The nif-
speciﬁc genes in Azotobacter vinelandii are involved in biogenesis of
Fe–S clusters for nitrogenase. The Escherichia coli isc- and suf- gene clus-
ter components perform the general synthesis of Fe–S proteins under
normal or oxidative stress conditions, respectively [39]. Orthologs of
the bacterial isc genes have been identiﬁed in yeast, plants and animals
[40,41], whereas the suf system is present mainly in cyanobacteria and
plants [40,42]. Particularly intense studies in bacteria and yeast have
providedmost of the insights into themechanismof Fe–S cluster assem-
bly (reviewed in [40,41]), revealing thatmanyof the general steps of the
pathway are common to all kingdoms of life.
Central to the initial stage of Fe–S cluster biogenesis is a cysteine
desulfurase (NFS1 in mammals, Nfs1 in yeast, and IscS in bacteria),
which, aided by its cofactor pyridoxal phosphate (PLP), abstracts sulfur
from free cysteine and delivers it to a dedicated scaffold protein, ISCU,
which provides the cysteine ligands to coordinate the nascent cluster
[38] (Fig. 1). The X-ray crystallographic structure of the E. coli apo-
IscU–IscS complex shows that each IscU molecule interacts with one
subunit of the IscS dimer, leading to a 2:2 stoichiometry [43], whereas,
to date, no eukaryotic structures of the core complex are available.
Using a co-expression approach, Colin and colleagues provided a bio-
chemical and biophysical characterization of the mammalian recombi-
nant ternary complex (named CplxIII) formed by NFS1, ISD11 and
ISCU, and of the quaternary complex (CplxIV) that forms when frataxin
is added, in the presence of two key substrates, iron and cysteine [44].
The mass of the CplxIII, as determined by electrospray ionization time
of ﬂight (ESI-TOF) mass spectrometry, suggested formation of a homo-
dimeric complex in which each unit has a 1:2:1 NFS1:ISD11:ISCU stoi-
chiometry. Frataxin, which was shown to interact with the preformed
ternary complex [45], was proposed to bind in a ratio of 1:2:1:1 in the
CplxIV complex (NFS1:ISD11:ISCU:FXN) [44].
The cysteine desulfurase activity of the yeast Nfs1 depends on bind-
ing to Isd11 [46], a protein not found in prokaryotes [47,48], and recent
studies in mammalian cells indicate that the human ortholog LYRM4
(also known as ISD11) is critical for NFS1 activity [49]. Isd11 is present
in the mitochondrial matrix of Saccharomyces cerevisiae, but it has
been detected in both the mitochondrial matrix and the nucleus of
mammalian cells [50], supporting previous reports that Fe–S cluster
biogenesis components, such as human NFS1 [51], ISCU [52], and the
late acting scaffold or speciﬁc carrier NFU1 [53], are also present and
functional in the cytosolic and/or nuclear compartments of mammalian
cells [54].
The source of iron for the nascent cluster remains to be identiﬁed,
but proposed donors include frataxin [55], which has acidic surface
patches to which iron binds with low afﬁnity, or a complex of glutathi-
one and glutaredoxin [56]. Structural modeling studies have recently
suggested that frataxin (Yfh1 in yeast) may function as an allosteric ef-
fector to either enhance, stabilize [44,45,57], or repress [58,59] the ac-
tivity of the biogenesis core complex, by interacting with NFS1 and
ISCU (Fig. 1). The yeast frataxin ortholog (Yfh1), independently from
Isu1 or Isd11, speciﬁcally stimulates binding of the substrate cysteine
to Nfs1, by inducing exposure of substrate-binding sites, which would
be otherwise buried [60]. Importantly, frataxin can compensate for
loss of Yfh1 in yeast, indicating that the human protein may act via a
pathway similar to the one identiﬁed in yeast [61,62].
Table 1
Diseases caused by defects in Fe–S cluster biogenesis.
Affected step Human
protein
Yeast
ortholog
Putative function(s) Disease Cause Incidence Tissue(s) affected References
Core [Fe–S] assembly NFS1 Nfs1 Cysteine desulfurase—
supplies inorganic sulfur
Infantile complex II/III
deﬁciency (IMC23D)
Missense mutation c.215GNA, p.Arg72Gln Three known patients Multisystem organ
failure
Farhan et al. [216]
Core [Fe–S] assembly ISD11
(LYRM4)
Isd11 Structural component of
the core complex,
required for NFS1 activity
Combined oxidative
phosphorylation defects
Missense mutation c.203GNT, p.R68L Two patients known Skeletal muscle and
liver
Lim et al. [49]
Core [Fe–S] assembly Frataxin
(FXN)
Yfh1 Component of the core
complex-allosteric
effector
Friedreich's ataxia (FRDA) Heterochromatin dependent repression of
FXN gene, due to expansion of the intronic
GAA repeat. About 4% of patients are
compound heterozygotes for the GAA
expansion on one FXN allele and an
inactivating mutation on the second one
1/50,000 births Dorsal root ganglia,
cerebellum and heart
Parkinson et al. [329];
Puccio et al. [330];
Stemmler et al. [55]
Core [Fe–S] assembly ISCU Isu1 and
Isu2
Primary scaffold for Fe–S
cluster assembly
ISCU myopathy Splicing defect IVS5 + 382GNC, or
heterozygosity for the splicing defect and the
missense mutation c.149GNA, p.G50E
Approximately 25
patients known
Skeletal muscle.
Combination of splicing
defect and missense
mutation affects heart
Kollberg et al. [231];
Mochel et al. [227];
Olsson et al. [229]
Core [Fe–S] assembly FDX2 Yah1 Electron donor for Fe–S
biogenesis
Mitochondrial muscle
myopathy
Disruption of the ATG translation initiation
site due to the homozygous mutation c.1ANT
Only one patient
known
Skeletal muscle Spiegel et al. [251]
[Fe–S] transfer to
speciﬁc recipients
GLRX5 Grx5 Fe–S carrier protein Sideroblastic anemia Splicing defect One patient Red blood cells Camaschella et al.
[109]; Ye et al. [108]
Non ketotic hyperglycinemia
with childhood-onset spastic
paraplegia, spinal lesion, and
optic atrophy
Homozygous deletion c.151_153delAAG,
p.K51del or compound heterozygosity for
p.K51del and 8 bp insertion
c.82_83insGCGTGCGG, resulting in premature
termination at amino acid 52
Three patients Primarily affects spinal
cord and optic nerve
Baker II et al. [256]
[Fe–S] transfer to
speciﬁc recipients
NFU1 Nfu1 Fe–S delivery to speciﬁc
recipients (LIAS)
Multiple Mitochondrial
Dysfunctions Syndrome 1
(MMDS1)
c.545GNA substitution near the splice donor
site of exon 6 in NFU1 predicting a
p.Arg182Gln substitution. Homozygosity for
c.622GNT (p.Gly208Cys), or compound
heterozygosity for c.622GNT and the splice site
c.545 + 5GNA
One patient for
c.545GNA. Nine
patients for c.622GNT
Early onset severe
systemic illness — No
tissue speciﬁcity
observed
Cameron et al. [133];
Navarro-Sastre et al.
[135]
[Fe–S] transfer to
speciﬁc recipients
BOLA3 Aim1 Fe–S delivery to speciﬁc
recipients (LIAS)
Multiple Mitochondrial
Dysfunctions Syndrome 2
(MMDS2)
Single base-pair duplication c.123dupA, in
exon 2, causing a frameshift that produces a
premature stop codon (p.Glu42Argfs⁎13)
One patient Central nervous system
and heart
Cameron et al. [133]
Homozygous missense mutation c.200TNA in
exon 3, p.I67N
Two patients Multisystem organ
failure
Haack et al. [134]
Non ketotic hyperglycinemia
with severe
neurodegeneration,
leukodystrophy,
cardiomyopathy and optic
atrophy
Homozygosity for c.136CNT, p.R46X
truncation
Three patients Primarily affects central
nervous system
Baker II et al. [256]
[Fe4–S4] assembly IBA57 Iba57 [Fe4–S4] assembly
component for a subset of
recipients
Multiple Mitochondrial
Dysfunctions Syndrome 3
(MMDS3)
Homozygous mutation c.941ANC, p.Gln314Pro Two patients Central nervous
system/skeletal muscle
Ajit Bolar et al. [36]
Mitochondrial
translation; complex I
assembly
NUBPL Ind1 Mitochondrial
translation; complex I
assembly
Childhood-onset
mitochondrial
encephalopathy and
complex I deﬁciency
c.166GNA, p.G56R substitution in NUBPL in
combination with deletion spanning exons
1–4. A second substitution was found in intron
9 (c.815-27TNC), resulting in aberrant splicing
At least seven patients
identiﬁed
Central nervous system,
skeletal muscle
Calvo et al. [146];
Wydro and Balk [247]
Mitochondrial export ABCB7 Atm1 Component of the
mitochondrial export
machinery
X-linked sideroblastic
anemia with cerebellar
ataxia (XLSA/A)
Several mutations close to or in
transmembrane domains of the ABC
transporter
At least twenty-three
patients identiﬁed
Central nervous system Allikmets et al. [273];
Bekri et al. [274];
D'Hooghe et al. [294];
Maguire et al. [275]
Mitochondrial iron
import
Mitoferrin1
(MFRN1)
MRS3 and
MRS4
Mitochondrial iron
importer
Variant erythropoietic
protoporphyria
Aberrant splicing ofMFRN1 transcript together
with mutations in FECH or ALAS2
Seven patients
identiﬁed
Erythroblastic cells Lecha et al. [296];
Wang et al. [309] 1495
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Fig. 1. Fe–S cluster biogenesis inmammalian cells: a general scheme of themain steps. (A) Assembly of a nascent Fe–S cluster upon the scaffold protein ISCU. A cysteine desulfurase NFS1
forms a dimer to which monomers of the primary scaffold ISCU bind at either end. ISD11 is a structural component of the core complex in eukaryotes, required for the activity of NFS1,
which, aided by its cofactor pyridoxal phosphate, provides sulfur, removed from cysteine, for the nascent cluster. Frataxin (FXN) is part of the core complex, potentially binding in a pock-
et-like region between NFS1 and ISCU. The cluster assembles upon ISCUwhen iron is provided together with the reducing equivalents that allow achievement of the ﬁnal electronic con-
ﬁguration of the cluster. (B) Cluster transfer to recipient apoproteins. A dedicated chaperone/cochaperone (HSPA9/HSC20) system facilitates cluster transfer from the primary scaffold
ISCU to recipient apoproteins or to intermediate carriers, which then target speciﬁc recipients. The cochaperone HSC20 interacts with ISCU through a patch of hydrophobic amino acid
residues in the C-terminus, and with the chaperone HSPA9 through the N-terminal domain (J-domain). The J-domain of HSC20 contains a conserved His (H), Pro (P), Asp
(D) tripeptide essential for activation of theATPase activity ofHSPA9. The energyderived fromactivation ofHSPA9drives a conformational rearrangement in the substrate-bindingdomain
of the chaperone (see text for further details), which is proposed to propagate a conformational change to its binding partner, ISCU (arrow 1). The conformational change is thought to
facilitate release of the cluster from themain scaffold, and allow protected transfer directly or via intermediate carriers to speciﬁc subsets of Fe–S recipient proteins. A nucleotide exchange
factor (NEF), known as Mge1 in yeast and SIL1 (or BAP) in humans exchanges ADP with ATP and completes the ATPase cycle of the chaperone (arrow 2).
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Fe–S clusters, are provided by ferredoxins (FDX1/2) and ferredoxin re-
ductase (FDXR) [32,63]. Ferredoxin has also been shown to facilitate re-
ductive coupling of two distinct [Fe2–S2] clusters into a single [Fe4–S4]
cluster on bacterial IscU in vitro [64].
3. Transfer of Fe–S clusters to recipient proteins
In vivo studies using a dominant negative mutant of the bacterial
scaffold IscU (IscUD39A in A. vinelandii, or IscUD35A in Archaeglobus
fulgidus), which remains trapped in a complex with the sulfur donor
IscS, and contains a nascent Fe–S cluster [65,66], showed that the clus-
ter assembly and release steps could be uncoupled. For the Fe–S clus-
ter release and transfer process, bacterial IscU interacts with two
dedicated partners, HscA and HscB, members of the DnaK/DnaJ (chap-
erone/cochaperone) families, respectively [67]. The Fe–S cluster
transfer machinery is highly conserved among different organisms
[40]. A cochaperone known as HSC20 in mammalian cells [68] (HscB
in bacteria [34], and Jac1 in S. cerevisiae [69]) binds to the scaffold pro-
tein ISCU, and forms a complex with its chaperone partner, HSPA9
(HscA in bacteria, and Ssq1 in S. cerevisiae), a member of the HSP70
heat shock protein family [37,70,71]. HSP70 homologues use the ener-
gy released by hydrolysis of ATP to drive conformational changes and
refolding of target proteins [72]. Both in the bacterial and mitochon-
drial systems, the C-terminal domain of the cochaperone is directly re-
sponsible for binding the scaffold protein ISCU, with three highly
conserved hydrophobic residues being of crucial importance for the
HSC20–ISCU interaction [37,73–75]. The crystal structures of HscB
from E. coli [76], of Jac1 from S. cerevisiae [74], and of human HSC20
[77] revealed common features among cochaperones dedicated to
Fe–S cluster biogenesis (Fig. 2). They have a conserved structural
core that consists of two domains arranged in a L-shaped fold. TheN-terminal J-domain, which contains an invariant histidine, proline,
aspartate (HPD)motif, is responsible for stimulating the ATPase activ-
ity of its HSP70 cognate chaperone [37,76,78,79], whereas the C-
terminal domain forms a three-helix bundle. The N-terminus of
human HSC20 (Fig. 2A) is clearly different from the specialized DnaJ
type III cochaperones of bacteria and fungi, in that it contains, adjacent
to the mitochondrial targeting sequence (residues 1–26 [70]), an
extra-domain, which harbors two CxxC modules (C41/C44 and C58/
C61) of unknown function (Fig. 2A). Their ability to coordinate a
zinc ion in vitro results in a zinc ﬁnger-like structure [77].
Recent studies in yeast indicate that the scaffold protein Isu1 binds
to the cysteine desulfurase Nfs1 or to the cochaperone, Jac1, in a mutu-
ally exclusive fashion [80]. Three highly conserved surface-exposed hy-
drophobic residues of Isu1 (L63, V72 and F94) were found to be critical
for the interaction with hydrophobic residues of Jac1 (L109, L105, and
Y163, respectively), or with residues of Nfs1 (M482, P478, and L479, re-
spectively), thus suggesting a functional role for the mutual exclusivity
of these interactions: competition between Jac1 and Nfs1 for binding to
Isu1 may play an important role in transitioning the Fe–S cluster bio-
genesis process from the core complex, which accomplishes the initial
assembly step, to the chaperone–cochaperone system that facilitates
transfer of the cluster to recipient proteins [80]. Evolutionary analyses
revealed that residues involved in these interactions are highly con-
served, thus suggesting that competition for binding to Isu1 is a point
of regulation between initial assembly and transfer of the nascent clus-
ter to recipient proteins that might be conserved from bacteria to
humans. Cochaperones serve a dual function in Fe–S cluster biogenesis:
they escort ISCU to the substrate binding domain of the HSP70 cognate
chaperone, and stimulate the ATPase activity of the chaperone, perhaps
driving a conformational change that could facilitate cluster release
from ISCU and delivery to the ﬁnal acceptor apoprotein or to intermedi-
ate carriers, which ultimately donate their clusters to speciﬁc recipients
Fig. 2. 3D-structures of cochaperones dedicated to Fe–S cluster biogenesis in H. sapiens (HSC20, panel A), S. cerevisiae (Jac1, panel B), and E. coli (HscB, panel C). Conserved amino acid
residues which interact with themain scaffold ISCU on the surface of the C-terminal domains of the cochaperones dedicated to Fe–S cluster biogenesis in humans (A), yeast (B), and bac-
teria (C): in blue are the hydrophobic amino acids (Leu,Met, and Phe), and in green thepolar residues (Tyr). TheHis (H), Pro (P), Asp (D) tripeptide in theN-terminal domains (J-domains)
of the cochaperones is indicated by arrows and colored in yellow. Two CxxC modules, which coordinate zinc in the crystal structure of human HSC20, are shown in red.
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of the IscU scaffold protein which mediate the interaction with the
HSP70 chaperone [34,82], and the crystal structure of the substrate
binding domain of HscA in complex with a peptide containing the
IscU recognition region (LPPVK) has been determined [83]. The crystal
structure of the substrate-binding domain of HSPA9 (residues 439–
590) is also available (PDB ID: 3N8E), and it shares 97% similarity to
the domain of bacterial HscA that binds IscU. The high degree of se-
quence homology translates into a remarkable structural conservation
of the domains of the two proteins (Fig. 3A–C).
3.1. Determining speciﬁcity of Fe–S cluster delivery: molecular features that
guide selection of recipient Fe–S proteins
A long-standing question in the ﬁeld has been related to the mo-
lecular mechanisms that guide selection of speciﬁc Fe–S recipientFig. 3. 3D-structural comparison between the substrate-binding domains of bacterial HscA and
parison of the crystal structures of the substrate-binding domain of HscA (residues 390–540
blue), and the region 439–590 of human HSPA9 (in violet). Panels A and B. Ribbon represent
the substrate binding domains of HscA and HSPA9. (C) Primary sequences of the regions of theproteins by the chaperone–cochaperone system. Most eukaryotes,
including humans, have a single multifunctional mitochondrial
chaperone, which participates in diverse cellular functions by virtue
of its ability to interact with an array of different J proteins (also
known as HSP40s) (for reviews, see [72,84,85]). HSP70s have a pro-
miscuous ATP-dependent substrate binding recognition activity.
Cochaperones are thought to play the crucial role of driving the func-
tional speciﬁcity of HSP70s [35,72,74], mostly through their C-
terminal domains, which can bind substrates on their own [86,87],
facilitate refolding of denatured proteins, and enhance cell viability
[88,89]. HSC20 is the sole human DnaJ type III cochaperone dedicat-
ed to Fe–S cluster biogenesis [68]. Mutations in HSC20 and in its
orthologs cause defects in Fe–S protein activities, mitochondrial
iron accumulation, and defective mitochondrial oxidative phosphor-
ylation in human cell lines [68], and in multiple experimental sys-
tems, including yeast [79,90] and ﬂy [91].human HSPA9, chaperones involved in Fe–S cluster biogenesis. Three-dimensional com-
, in cyan) in complex with a peptide containing the IscU recognition region (LPPVK in
ation (A) and equivalent surface representation (B) of the two overlapped structures of
two HSP70s showed in (A) and (B).
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ter delivery by binding to a conserved leucine–tyrosine–arginine (LYR)
motif present in speciﬁc recipient Fe–S proteins or in accessory factors
that likely assist Fe–S cluster insertion into target apoproteins [37]. Sev-
eral HSC20 binding partners were identiﬁed in a stringent yeast two-
hybrid (Y2H) screen, a method of identifying direct molecular interac-
tions between pairs of proteins, and some of them were validated
in vivo by co-immunoprecipitation studies. Notably, multiple individual
clones identiﬁed in the screen encoded succinate dehydrogenase sub-
unit b (SDHB), the Fe–S cluster containing subunit of complex II,
which has three Fe–S centers of different nuclearities. To identify the
potential motifs in SDHB that could bind HSC20, the SDHB primary se-
quence was subdivided into multiple peptides, which were cloned
into Y2H prey constructs to screen 50 to 100 subclones of varying
sizes for their ability to interact with HSC20. Three independent binding
sites for HSC20 were identiﬁed on SDHB, and two of these were itera-
tions of the LYR motif. The LYR motif was present in several other pro-
teins selected in the Y2H (i.e. EPRS, HELZ, SPC25, GTF2E2, ETFA), and
also in LYRM7, the Rieske Fe–S protein chaperone of complex III [92]
and an annotated member of the LYR family [93] (Conserved Domains
Accession: cl05087). The LYR motif family contains at least eleven pro-
teins in humans in which the LYR tripeptide resides close to their N-
terminus. Members of the LYR family are SDHAF1 (LYRM8), a bona
ﬁde succinate dehydrogenase complex assembly factor [94], ISD11
(LYRM4), a component of the initial Fe–S assembly complex [50],
LYRM7, a complex III assembly factor, and two subunits of respiratory
chain complex I known as NDUFA6 and NDUFB9 (also annotated as
LYRM6 and LYRM3, respectively) [93]. Several LYR motif proteins do
not have a known function, such as LYRM2, LYRM5, and LYRM9, where-
as others have been only partially characterized in yeast, such as ACN9
(acetate non-utilizing protein 9) [95,96], or FMC1 (formation of mi-
tochondrial complexes protein 1) [97]. Interestingly, human ISD11
and LYRM7 share high sequence homology with their yeast
orthologues, Isd11 andMzm1, respectively, and they perform similar
functions [50,92], whereas human SDHAF1 has low similarity to the
yeast ortholog Sdh6 and failed to restore respiration in a Sdh6 null
background (ΔSdh6) yeast strain [94]. The functional signiﬁcance of
the common LYR motif was completely unknown when the Pfam clan
Complex1_LYR-like superfamily (CL0491) was built by P.C. Coggill
[98]. Based on bioinformatics analyses, the motif was deﬁned as a
tripeptide in which the ﬁrst position was generally an aliphatic hydro-
phobic amino acid such as isoleucine or leucine, the secondwas an aro-
matic amino acid such as tyrosine or phenylalanine, and the third was a
positively charged arginine or lysine. The tripeptide was followed by a
conserved phenylalanine separated from LYR by about twenty-ﬁve res-
idues [93]. The coimmunoprecipitation and Y2H studies indicated that
LYR motifs present in known recipient Fe–S proteins (i.e. SDHB) or in
accessory factors (i.e. SDHAF1, LYRM7) mediated an interaction with
the cochaperone HSC20, and likely guided insertion of Fe–S clusters
into the Fe–S subunit of respiratory chain complex II (Fig. 4), and, pos-
sibly, into complex III [37]. In fact, LYRM7,which has been characterized
as a complex III assembly factor, binds UQCRFS1 [92], the Rieske Fe–S
protein of complex III, and engages the HSC20–HSPA9–ISCU complex
[37], suggesting that the LYRM7–HSC20 interaction might guide the in-
sertion of the [Fe2–S2] cluster into UQCRFS1. The role of the complex I
subunit LYRM6 (also known as NDUFA6 and as NB4M in the yeast
Yarrowia lipolytica) has been recently characterized [99]. Chromosomal
deletion of NB4M in Y. lipolytica or mutagenesis of the LYR tripeptide
and of a conserved downstream phenylalanine into alanines caused
loss of the [Fe4–S4] N2 cluster, which is the last Fe–S center in the as-
cending electron transfer sequence of the matrix arm of complex I
with the highest redox potential, and totally abrogated the ubiquinone
reductase activity of complex I, despite the fact that all the central sub-
units of the complex were intact. This ﬁnding suggests that NB4M
(NDUFA6) is required for proper incorporation of the N2 [Fe4–S4]
center, and for the function of complex I. Notably, NDUFS8, whichligates two [Fe4–S4] clusters, contains a conserved LYR motif in a
non-canonical position, at its C-terminus. As only 14 of the 45 com-
plex I subunits have a catalytic function [100], some of the accessory
or supernumerary subunits may contribute to the assembly and sta-
bility of the complex, and the LYR-containing subunits may aid inser-
tion of some of the Fe–S clusters.
A second consensus sequence, KKx6–10KK, was identiﬁed in the
screening of the SDHB peptides that interacted with HSC20 through
its C-terminal domain. Interestingly, human glutaredoxin 5 (GLRX5)
has a similar pattern of lysines at its C-terminus (K139K140x10K151K151)
and was found to interact with HSC20 in vivo [37]. The yeast ortholog
Grx5 interacts with Ssq1, the mitochondrial chaperone dedicated to
Fe–S cluster biogenesis [101].
The function of the LYR and KKx6–10KK motifs may be very depen-
dent on their molecular context and structural location [37]. Other fea-
tures may deﬁne which LYR proteins engage HSC20 and the transfer
apparatus, and these features will likely be deﬁned as more LYR and
Fe–S proteins are studied.
3.2. Intermediate carriers and secondary scaffolds that deliver Fe–S clusters
to recipient proteins
Glutaredoxin 5 has been characterized as one of many intermediate
carriers which are involved in the transfer of Fe–S clusters downstream
of the scaffold protein ISCU, in yeast [41,101,102], zebraﬁsh [103], and
humans [104–109]. In eukaryotes, monothiol glutaredoxins localize to
mitochondria or chloroplasts and have been implicated in Fe–S cluster
biogenesis (for recent reviews, see references [104,110–112]), whereas
multidomain Glrxs (i.e. yeast Grx3/4 and human GLRX3) localize to the
cytosolic/nuclear compartment and are proposed to play dual roles in
iron trafﬁcking and regulation [113–116]. The ﬁrst crystal structure of a
[Fe2–S2]-bridged Grx homodimer, published in 2009 for E. coli Grx4,
showed that two GSH molecules were held in place by non covalent in-
teractions with the binding pocket of each Grx4 monomer and by cova-
lent linkages to the cluster [117]. A more recent crystal structure of
human GLRX5 revealed a similar coordination for the [Fe2–S2] cluster;
however, in this structure, two [Fe2–S2]-bridged homodimers interacted
to form a tetramer [118]. The current working model to describe the
role of glutaredoxins in Fe–S cluster biogenesis proposes that they tran-
siently accept a [Fe2–S2] cluster and engage the chaperone–cochaperone
transfer apparatus in order to facilitate its insertion into ﬁnal acceptor
apoproteins [37,101]. An alternative cluster transfer mechanism hypoth-
esizes that a [Fe2–S2] cluster coordinated by four glutathione molecules
might be exchanged with the cellular Fe–S cluster biogenesis compo-
nents [119,120]. Glutaredoxins have been linked to another family of
widely distributed proteins, the BolA-like proteins, by bioinformatics
analyses, yeast two-hybrid and afﬁnity puriﬁcation studies, both in pro-
karyotes and in eukaryotes, including plants [121–125]. BolA proteins
were initially identiﬁed in E. coliwith the observation that their overex-
pression promoted a switch from rod-shaped to rounded cell morphol-
ogies [126]. The Grx3/Grx4 proteins are involved in iron regulation in
yeast, by forming a complexwith the BolA-like protein, Fra2, and ligating
a [Fe2–S2] cluster coordinated by the Grx active site cysteine of Grx3/
Grx4, a conserved histidine in Fra2 (His103), and a cysteine from gluta-
thione [114,127,128] (for a review on Grxs and BolA-like proteins, see
reference [105]). Under low iron conditions or upon disruption of mito-
chondrial Fe–S cluster biogenesis, the Fra2/Grx3/Grx4 signaling pathway
is proposed to interpret and transmit a signal to the iron-responsive tran-
scription factor Aft1 (and presumably its paralog Aft2), allowing Aft1 to
accumulate in the nucleus and activate the iron regulon [114–116],
which encodes proteins involved in iron uptake, transport, and storage
[129–131]. Under iron-replete conditions, an inhibitory signal is trans-
mitted to Aft1 (and/or Aft2) that induces its multimerization and export
from the nucleus via its interaction with the exportin Msn5 [132]. Mam-
mals have three BOLA homologues, named BOLA1, BOLA2, and BOLA3, of
unknown functions. Recently, mutations in human BOLA3 have been
Fig. 4. Schematic representation of Fe–S cluster delivery to speciﬁc recipients mediated by binding of HSC20 to LYR motifs. Fe–S cluster incorporation into succinate dehydrogenase B
(SDHB): in SDHB, two LYR motifs (IYR and LYR) engage the HSC20–HSPA9–ISCU complex, which assists incorporation of three Fe–S clusters within the ﬁnal structure of complex II. An
important aspect of the model is that the ﬁrst motif may enter the mitochondrial matrix ﬁrst, as the SDHB polypeptide translocates from the site of its synthesis in the cytosol, to its des-
tination, themitochondria. The accessibility of the ﬁrst motif would not be yet affected by C-terminal sequences and secondary structure formation. Indeed, donation of a [Fe2–S2] cluster
could determine secondary structure by driving folding around the Fe–S cluster, to which cysteines 93, 98, 101, and 113 bind with high afﬁnity. SDHAF1 (LYRM8), an assembly factor for
complex II and an annotated member of the LYR motif family, associates with SDHB through a non-LYR binding site that is not yet fully deﬁned, but that resides between the two LYR
motifs. In our working model, SDHAF1 binds to SDHB through a non-LYR portion of its sequence and utilizes its own LYR motif to position an ISCU–HSC20–HSPA9 complex near to Fe–
S transfer complexes directly associated with the second LYR binding site of SDHB. The propensity of HSC20 to dimerize may allow two holo-ISCU molecules at neighboring binding
sites to reorganize their adjacent [Fe2–S2] centers, thus coalescing into the [Fe4–S4] and [Fe3–S4] clusters of mature SDHB. Again, the primary peptide would be driven to fold around
the newly incorporated Fe–S clusters, potentially explaining how some Fe–S centers can be deeply buried in proteins. The structures reported are relative to porcine succinate dehydro-
genase complex (96% identical to human. PDB ID: 3SFD).
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chondrial dysfunctions syndrome 2 [133,134], caused by defects in the
biogenesis of the Fe–S cluster enzyme lipoic acid synthase (LIAS).
Human BOLA3 has two isoforms (NM_001035505.1 and NM_212552.2)
that result from alternative splicing, with isoform 2 lacking exon 3, and
they are both predicted to localize to mitochondria with 95% probability.
Human NFU1, which was shown to accommodate a [Fe4–S4] cluster [53],
has been recently characterized as a late acting factor speciﬁcally required
for maturation of lipoic acid synthase, rather than as an alternative scaf-
fold acting in parallel to ISCU, based on the fact that mutations in NFU1
are associated mainly with defective lipoic acid (LA) metabolism [133,
135,136], whereas other Fe–S dependent processes are less affected.
The A-type scaffolds are thought to support the biogenesis of a distinct
subset of Fe–S proteins. The isc and suf operons of bacteria encode two
A-type proteins IscA and SufA, respectively, which were found to be in-
volved in the maturation of some [Fe4–S4] proteins, such as aconitase
and LIAS [38,137]. An additionalmember of this family, ErpA, is speciﬁcal-
ly involved in isoprenoid biosynthesis [138]. Eukaryotes have two A-type
ISC proteins that share common primary structure features, but have dif-
ferent functions [139,140]. Yeast Isa1 and Isa2 forma complexwith Iba57,
a protein that was initially identiﬁed in a genome-wide screen for
S. cerevisiaemutants that required supplementation of lysine and gluta-
mate for growth [141]. Iba57was later found to be required for Fe–S clus-
ter incorporation into aconitase and homoaconitase and into the radical-
SAM Fe–S enzymes biotin synthase and lipoic acid synthase [141,142].
The human genome encodes two A-type proteins, named ISCA1 and
ISCA2, related to S. cerevisiae Isa1 and Isa2, respectively, thought to be
necessary for biogenesis of several [Fe4–S4], but not [Fe2–S2], enzymes
[143]. Cells deﬁcient in IBA57 exhibited a phenotype similar to ISCA1-
or ISCA2-depleted cells. Consistent with the role of ISCA1/ISCA2 and
IBA57 in the biogenesis of [Fe4–S4] clusters for a subset of mitochondrial
proteins, a mutation affecting the stability of IBA57 was recently found
in two patients with severe myopathy and encephalopathy associated
with compromised activities of the lipoic acid dependent enzymes, indi-
cating defectivematuration of LIAS [36]. Themitochondrial P-loopNTPase
IND1 (Fe–S protein required for NADH dehydrogenase) was initially
thought to be an iron–sulfur protein required for effective complex Iassembly in the yeast Yarrowia lipolitica [144]. Studies of the human
ortholog NUBPL (nucleotide–binding protein–like) similarly suggested
that the protein was a speciﬁc Fe–S cluster targeting factor for complex I
[145]. NUBPL was therefore included in a list of 103 candidate genes for
next-generation exon sequencing in patients with complex I deﬁciency
[146]. Recent studies of IND1 in Arabidopsis thaliana (INDH) were able
to untangle primary from secondary phenotypes caused by inactivating
mutations in INDH, anddemonstrated that INDHhas a primary role inmi-
tochondrial translation [147]. Impairment of complex I likely was due to
the fact that seven of its subunits are encoded by the mitochondrial ge-
nome and translated in the matrix.
4. Cytosolic iron–sulfur cluster assembly machinery (CIA)
Details of how the mitochondrial and cytosolic Fe–S cluster assembly
pathways are connected have been the subject of intense scrutiny, and
the paradigm that Fe–S clusters are assembled solely in themitochondrial
matrix based on studies in yeast does not necessarily extrapolate tomam-
malian cells [30], where extra-mitochondrial isoforms of the core compo-
nents NFS1 [51,148], ISD11 [50], and ISCU [54], and of the intermediate
carrierNFU1 [53], havebeen identiﬁed, togetherwithnine additional pro-
teins, highly conserved from yeast to humans, which constitute the cyto-
solic iron–sulfur assembly machinery (CIA) [149]. Interestingly, a pool of
HSC20 is present in the cytosol of mammalian cells [37,68], and the
cochaperone from A. thaliana (AtHscB), which is able to rescue the Jac1
yeast knock out mutant, localizes both to themitochondrial and cytosolic
compartments [150], together with the scaffold protein AtIscU1 and the
specialized chaperone dedicated to Fe–S cluster biogenesis, AtHscA
[150].
An “export system” has been proposed to transport a speciﬁc sulfur-
containing compound out of the mitochondrial matrix, which can then
be utilized for cytosolic Fe–S cluster biogenesis [107]. The ABC transporter
ABCB7 (Atm1 in yeast) is part of the putative export machinery, together
with the sulfhydryl oxidase GFER (yeast Erv1) [151], and glutathione
[152]. Defects in ABCB7/Atm1 cause impaired cytosolic Fe–S cluster pro-
tein activities and iron accumulation in mitochondria [153,154]. In
yeast, Fe–S cluster biogenesis in the cytosol is proposed to initiate with
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posed of the two P-loop NTPases Cfd1 and Nbp35 (NUBP2, NUBP1 in
humans, respectively — see Table 2) [155]. This proposed initial step
also requires transfer of electrons from NADPH to the diﬂavin reductase
Tah18 and the Fe–S protein Dre2 (NDOR1 and CIAPIN1 (anamorsin), re-
spectively, in humans) [156]. The second stage (transfer of the transiently
bound [Fe4–S4] cluster from Cfd1-Nbp35 to recipient apoproteins) is ac-
complished by the iron-hydrogenase-like protein Nar1 (also known as
NARFL or IOP in humans) [157], and the CIA targeting complex formed
of Cia1, Cia2 and Mms19 (CIAO1, CIA2B, CIA2A and MMS19 in humans)
[158–161]. MMS19 is part of the late-acting CIA complex, together with
CIAO1 and CIA2B, that speciﬁcally targets cytosolic Fe–S proteins that
are linked to nucleotide and DNA metabolism (i.e. glutamine
phosphoribosylpyrophosphate amidotransferase (GPAT) and
dihydropyrimidine dehydrogenase (DYPD), DNA polymerase δ
(Polδ), xeroderma pigmentosum protein D (XPD), the RAD3-like
helicases RTEL1 (regulator of telomere length protein 1) and Fanconi
anemia protein J (FANCJ)) [159,160]. Conversely, MMS19 is dispens-
able for the maturation of the Fe–S cluster for cytosolic aconitase
(ACO1/IRP1), which is believed to acquire its cluster from a distinct
complex formed by CIAO1 and CIA2A [161]. CIAO1 has indeed been
shown to form mutually exclusive complexes with either CIA2A or
CIA2B–MMS19. The CIAO1–CIA2B–MMS19 complex appears to facil-
itate maturation of most of the cytosolic–nuclear Fe–S proteins,
whereas CIA2A seems to be speciﬁcally involved in the biogenesis
of Fe–S clusters for cytosolic aconitase, which is converted into the
IRE (Iron Responsive Element)-binding form when cells are CIA2A
depleted [161]. An additional role of CIA2A in cellular iron regulation
may involve stabilization of IRP2 [159,161], which does not contain
an Fe–S cluster, but undergoes iron- and oxygen-dependent degra-
dation by the proteasome [162,163].Table 2
Proteins involved in Fe–S cluster biogenesis in eukaryotes.
Assembly step Human protein Yeas
Core Fe–S cluster assembly NFS1 Nfs1
Core Fe–S cluster assembly ISCU Isu1
Core Fe–S cluster assembly ISD11 (LYRM4) Isd1
Core Fe–S cluster assembly Frataxin (FXN) Yfh1
Core Fe–S cluster assembly Ferredoxins (FDX1, FDX2) Yah
Core Fe–S cluster assembly Ferredoxin reductase (FDXR) Arh1
[Fe–S] cluster transfer Mortalin (HSPA9, GRP75) Ssq1
[Fe–S] cluster transfer HSC20 Jac1
[Fe–S] cluster transfer SIL1 (BAP) Mge
[Fe–S] cluster transfer GLRX5 Grx5
[Fe–S] cluster transfer-late acting factor ISCA1 Isa1
[Fe–S] cluster transfer-late acting factor ISCA2 Isa2
[Fe–S] cluster transfer-late acting factor IBA57 Iba5
[Fe–S] cluster transfer-late acting factor NFU1 Nfu1
[Fe–S] cluster transfer-late acting factor BOLA3 Aim
[Fe–S] cluster transfer-late acting factor NUBPL Ind1
Mitochondrial export of an unknown compound
to the cytosol
ABCB7 Atm
Mitochondrial export of an unknown compound
to the cytosol
GFER Erv1
Extramitochondrial [Fe–S] biogenesis NUBP1 Nbp
Extramitochondrial [Fe–S] biogenesis NUBP2 Cfd1
Extramitochondrial [Fe–S] biogenesis NARFL (IOP) Nar1
Extramitochondrial [Fe–S] biogenesis CIAO1 Cia1
Extramitochondrial [Fe–S] biogenesis NDOR1 Tah1
Extramitochondrial [Fe–S] biogenesis CIAPIN1 Dre2
Extramitochondrial [Fe–S] biogenesis MMS19 MET
Extramitochondrial [Fe–S] biogenesis FAM96A (CIA2A)
Extramitochondrial [Fe–S] biogenesis FAM96B (CIA2B)5. Defects in Fe–S cluster biogenesis and human diseases
As previously discussed, Fe–S clusters are involved in several funda-
mental cellular processes, and it is therefore not surprising that muta-
tions that affect the components of the basic Fe–S biogenesis pathway
cause diseases in humans (see Table 1).
5.1. Friedreich's ataxia (MIM# 229300)
Friedreich's ataxia (FRDA) is an autosomal recessive neurodegen-
erative disorder caused primarily by a homozygous GAA repeat ex-
pansion within intron 1 of the frataxin (FXN) gene, located on
chromosome 9q21.1 [164]. Approximately 4% of FRDA patients are
compound heterozygotes, having a GAA repeat expansion on one al-
lele and an inactivating or loss-of-function mutation, such as a point
mutation [165,166] or a deletion/duplication [167–169] on the other
allele. The incidence of FRDA is 1–2 in 50,000 in Caucasian populations
with an equal occurrence in both genders [170,171] and an estimated
carrier frequency of 1:60 to 1:100 [172]. Unaffected individuals have
up to 43 GAA repeats, whereas FRDA patients have 44 to 1700, most
commonly between 600–900 GAA repeats [172,173]. Genotype/pheno-
type correlation studies have been carried out to assess the relationship
between the length of the GAA-triplet repeat and the clinicalmanifesta-
tions in FRDA [174]. Larger GAA repeat expansions correlate with in-
creased severity of FRDA disease and with earlier age of onset [174,
175]. The GAA-triplet repeat leads to transcriptional silencing of FXN
that is caused most likely by heterochromatin condensation of the
locus [176], which drastically reduces transcription of FXN by 70%–
95% [177,178]. A recent investigation reports on the transcriptional
silencing of FXN, caused by formation of RNA/DNA hybrids (named
R-loops) [179], which are stable and co-localize with repressivet ortholog (Putative) function(s)
Sulfur donor
and Isu2 Scaffold protein
1 Eukaryotic speciﬁc accessory factor required for cysteine desulfurase
activity
Iron donor (?) Allosteric effector (?) Cysteine desulfurase derepressor
1 Electron transport
Electron transport
Molecular chaperone
Cochaperone. It binds target proteins that contain the LYR motif
1 Nucleotide exchange factor
Intermediate carrier
[Fe4–S4] assembly
[Fe4–S4] assembly
7 [Fe4–S4] assembly
Dedicated targeting factor for LIAS
1 Dedicated targeting factor for LIAS
Mitochondrial translation; complex I assembly
1 ABC transporter proposed to export a sulfur containing compound
from mitochondria
FAD-dependent sulfhydryl oxidase in intermembrane space that
catalyzes disulﬁde bond formation. Required for cytosolic Fe–S cluster
assembly
35 P-loop NTPase that forms a heterotetrameric Fe–S scaffold with NUBP2
P-loop NTPase that forms a heterotetrameric Fe–S scaffold with NUBP1
Interacts with CIAO1 and can mediate Fe–S cluster transfer
WD40 repeat protein that interacts with NARFL and can mediate Fe–S
cluster transfer
8 NADPH-dependent diﬂavin oxidoreductase 1. Electron transport
Electron transport
18 Adapter between early acting CIA components and a subset of cellular
target Fe–S proteins
Part of a complex that facilitates Fe–S cluster transfer to IRP1
Part of a complex that facilitates Fe–S cluster transfer to speciﬁc
recipients (i.e. GPAT, DYPD)
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scription of FXN. Using RNase protection assays, Bidichandani et al.
showed that the GAA repeat per se interferes with in vitro transcription
of FXN in a length-dependent manner [180], consistent with the ob-
served negative correlation between GAA triplet-repeat length and
the age at onset of disease. Frataxin is a ubiquitous mitochondrial pro-
tein whose exact function is still controversial: however both in vitro
and in vivo studies support the notion that the protein plays a crucial
role in Fe–S cluster biogenesis [45,57,181]. FXN deﬁciency leads to pro-
gressive loss of large sensory neurons in the dorsal root ganglia (DRG)
and degenerative atrophy of the posterior columns of the spinal cord,
resulting in symptoms of progressive ataxia, muscleweakness, and sen-
sory deﬁcits [182]. Non-neurological symptoms include hypertrophic
cardiomyopathy and increased incidence of diabetes [183–185]. Cardiac
failure is the most common cause of mortality. The condition is charac-
terized by three distinctive and prominent biochemical features: defec-
tive maturation of Fe–S cluster enzymes such as aconitase and the
respiratory chain complexes [186,187], mitochondrial iron accumula-
tion [108,188–190], and the presence of oxidative stress markers in
blood samples [191–193]. Heterozygous individuals who carry the
GAA expansion on only one FXN allele have no clinical symptoms,
though frataxin levels are markedly reduced [194], whereas inactiva-
tion of both alleles is embryonically lethal in plants and mice [195,
196], and leads to larval stage arrest in Caenorhabditis elegans [197], in-
dicating that complete loss of FXN is not compatible with life in higher
organisms.
A crucial question regards understandingwhy speciﬁc tissues develop
pathology in Friedreich's ataxia, whereas others are spared. Tissues with
high levels of frataxin and that are generally highly mitochondria-depen-
dent, such as the kidneys and liver, are not obviously affected in FRDA
[164]. The tissue-speciﬁc phenotypes of FRDAmight arise from the critical
requirement of speciﬁc isoformsof FXN,whichmaybe severely decreased
in the disease. Interestingly, two rare frataxin isoforms have been recently
identiﬁed [198], and their expression was substantially reduced in the
heart (isoform III), and cerebellum (isoform II) of a FRDApatient, suggest-
ing that novel expression patternsmay explain some FRDA tissue speciﬁc
phenotypes.
The fact that frataxin is highly conserved from bacteria to humans led
to the development of multiple cellular and animal model systems that
have provided insights into the function of frataxin and the pathophysiol-
ogy of FRDA. Murine FXN is 73% identical to the human protein, thus ren-
dering the mouse a relevant model system in which to investigate the
pathogenesis of FRDA [199]. However, only humans and primates have
the GAA repeat expansion in the ﬁrst intron [200], and there is currently
nomodel that is able to reproduce all the symptoms that occur in patients.
The combination of data from all the available cell and animalmodels can
help to understand disease processes and develop therapeutic strategies.
Several conditional knockout mouse models, based on the Cre–loxP sys-
tem,were generated to investigate the consequences of frataxindepletion
in tissues affected in FRDA (particularly nervous system, heart and pan-
creas). Together, these models reproduce most of the features of the dis-
ease, including hypertrophic cardiomyopathy [201], spinocerebellar and
sensory ataxia [201–203], and some aspects of the diabetes [204], though
they lack the GAA-triplet expansion, which causes incomplete loss of ex-
pression inmost of the cell types of interest. The resulting phenotypes are
therefore partial as they depend on low levels of frataxin in a distinct tis-
sue cell type, in which some cells have full expression, whereas others
have completely lost expression. Thus far, two different strategies have
been used to generate mouse models that harbor the GAA-repeat expan-
sion, in order tomimic the FRDA condition in which a reduced amount of
FXN is present in all tissues: a knock-in approach based on the insertion of
a (GAA)230 triplet repeat into the ﬁrst intron of themouse FXN locus (KIKI
mice) [205], and the generation of transgenic mice in which the entire
human FXN gene within a human yeast artiﬁcial chromosome (YAC)
was inserted onto a mouse FXN null background [206]. The various
mouse models highlight two main points: on one hand, the conditionalknockouts recapitulate important features of FRDA, but they lack the ge-
netic context, whereas the GAA repeat expansion-based knock-in and
transgenic models carry a GAA triplet expansion, but they exhibit only a
mild phenotype. Cell lines derived from FRDA patients are the most rele-
vant frataxin-deﬁcient in vitromodels, as they carry the human FRDAmu-
tations. Fibroblasts and lymphocytes from patients are easily accessible
but these cell types do not exhibit the strong biochemical phenotype as-
sociated with FRDA, despite having reduced frataxin levels [186,207]
and higher susceptibility to oxidative stress [193,208]. The most interest-
ing cells to study would be neurons and cardiomyocytes, which are par-
ticularly affected in FRDA, but not accessible from patients. To
circumvent this problem, primary ﬁbroblasts have been used and
reprogrammed into embryonic-like cells, known as induced pluripotent
stem cells (iPSCs), that are theoretically able to differentiate into virtually
all cell types of the human body [209]. These models explained several
biochemical features associated with FRDA, such as the fact that
intramitochondrial iron accumulation develops after inactivation of Fe–
S-dependent enzymes [181,187]. One mechanism proposed to explain
iron accumulation in FRDA patients is related to cytosolic iron deﬁciency,
whichwould impair biogenesis of extra-mitochondrial Fe–Sproteins, par-
ticularly cytosolic aconitase, which is converted into the IRE binding form
(IRP1), increasing TfR expression and reducing ferritin levels [210]. An ad-
ditional effect is the stabilization of IRP2, again by cytosolic iron deﬁcien-
cy, that further promotes iron uptake. Moreover, expression of the
mitochondrial iron importer, mitoferrin, was found to be increased in
the heart of frataxin deﬁcient mice [211]. The resulting mitochondrial
iron accumulationmaypromote signiﬁcant productionof reactive oxygen
species (ROS) [187,212,213]. Several pharmacological approaches have
been tested to treat the downstream events of the frataxin deﬁciency,
such as mitochondrial iron overload (deferiprone), and oxidative stress
(ibedenone), or alternatively to increase frataxin levels (reviewed in
[214]). Recently, an extraordinary result and a promising potential thera-
peutic approach for FRDApatients came from a gene therapy-based strat-
egy. Cardiomyocytes from a conditional mouse model with complete
frataxin deletion in cardiac and skeletal muscle were rapidly rescued
and remodeled by adeno-associated viral expression of human FXN
[215].
5.2. Infantile mitochondrial complex II/III deﬁciency (IMC23D) caused
by a missense mutation in NFS1 on chromosome 20q11.22 (MIM#
603485)
A novel fatal autosomal recessive disease has been identiﬁed in three
children of healthy third cousinswithin anOldOrderMennonite commu-
nity [216], characterized by lactic acidosis, hypotonia, respiratory chain
complex II and III deﬁciencies in muscle, multisystem organ failure and
abnormal mitochondrial morphology. The causative mutation led to sub-
stitution of Arg72 into Gln in the cysteine desulfurase (NFS1). No NFS1–
ISD11 interactionwas detected in patient ﬁbroblasts, indicating complete
disruption of themultimeric complex that provides sulfur for Fe–S cluster
biogenesis [216]. Human NFS1 has been shown to localize either tomito-
chondria or to the cytosol and nucleus as a result of initiation of transla-
tion at alternative in-frame AUGs [51]. Besides its role in Fe–S cluster
biogenesis, NFS1 is essential in the cytosol for providing sulfur in themo-
lybdenum cofactor biosynthetic pathway [217], which expands the phys-
iological signiﬁcance of the cysteine desulfurase, as sulﬁte oxidase,
xanthine oxidoreductase and aldehyde oxidase are essential cytosolic en-
zymes that require themolybdenumcofactor for their function (reviewed
in [218]). Moreover, the cysteine desulfurase is also known to be impor-
tant in sulfuration of tRNAs [219]. So far, two studies have examined the
physiological consequences of cellular NFS1 depletion via small interfer-
ing RNA-mediated gene silencing approaches [220,221]. Depletion of
NFS1 in murine NIH3T3 ﬁbroblasts led to compromised mitochondrial
oxidative phosphorylation and reduced activities of severalmitochondrial
and cytosolic Fe–S enzymes (i.e.mitochondrial and cytosolic aconitases
and xanthine oxidase) [221]. Similar effects resulted from knock down
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ciency in humans, and the early onset of clinical symptoms together
with the fatal outcome of the disease stresses the crucial importance of
NFS1 for human physiology.
5.3. A homozygous missense mutation in LYRM4 on chromosome 6p25
causes deﬁciency of multiple respiratory chain complexes (MIM# 615595)
Massively parallel sequencing (MitoExome sequencing) of N1000mi-
tochondrial genes identiﬁed a homozygous mutation in LYRM4/ISD11
(c.203GNT, p.R68L) in a 20-year-old man (P1) from a consanguineous
family of Lebanese and Syrian ancestry. The samemutationwas also pres-
ent in his cousin who had a more severe phenotype and died at two
months of age (P2). The patients were diagnosed with a mitochondrial
disorder characterized by combined oxidative phosphorylation deﬁcien-
cies in skeletal muscle and liver [49]. In the newborn period, P1 experi-
enced respiratory distress, hypotonia, and severe lactic acidosis. Other
features included elevated liver enzymes. He slowly improved with
supportive therapy over the following weeks. Laboratory studies on
patient liver and muscle samples revealed decreased activities of
mitochondrial respiratory chain complexes I, II and III in both
patients. P2 also had complex IV deﬁciency in skeletal muscle. Sever-
al Fe–S proteins other than complexes I–III, such as aconitase and
ferrochelatase, were also deﬁcient in P1. As cysteine requirements are
higher at birth than later in life, Lim and colleagues explained the differ-
ent clinical outcomes between the two individuals by considering pos-
sible differences in the dietary neonatal availability of cysteine between
them [49]. The R68L mutation was shown to affect the stability of
LYRM4, which was undetectable by western blot in P2 skeletal muscle
or in the liver tissue from both patients. The mutant yeast ortholog
Isd11R71L failed to rescue growth of an Isd11-null strain, consistent
with the loss of function effect of themutation. In vitro studies revealed
that Isd11R71L, despite binding to NFS1, was unable to activate the
cysteine desulfurase enzymatic activity. Overall this ﬁnding under-
scores the crucial role of ISD11 as part of the core complex involved in
Fe–S cluster biogenesis, and the phenotype described is consistent
with a defect in the early step of Fe–S assembly that affects multiple
enzymes.
5.4. ISCU myopathy, also known as hereditary myopathy with lactic ac-
idosis or as Swedish myopathy, caused by homozygous or compound
heterozygous mutations in the ISCU gene on chromosome 12q24
(MIM# 255125)
Hereditarymyopathywith lactic acidosis (HML), also knownas Swed-
ish myopathy with exercise intolerance [222,223], was ﬁrst described in
the 1960s and is an autosomal recessive muscular disorder characterized
by childhood onset of exercise intolerancewith cramping, dyspnea, palpi-
tations andmuscle weakness. Biochemical features of the disease include
lactic acidosis and, rarely, rhabdomyolysis and myoglobinuria [222,224,
225], with impaired muscle oxidative phosphorylation, deﬁcient succi-
nate dehydrogenase [224,226] and aconitase [227,228] activities, and
the presence of iron aggregates in mitochondria [227,228]. Further bio-
chemical characterization of mitochondria from HML patients [228]
showed that, in addition to severe deﬁciencies of complex II and
aconitase, complex III activity decreased to 37% of normal, and immuno-
blot analysis of complex I revealed reduced levels of several subunits, sug-
gesting a generalized abnormality of the synthesis, import, processing or
assembly of a group of Fe–S cluster containing enzymes. In 2008, two
groups identiﬁed the disease causing mutation in patients from northern
Swedenwith HLMwithin a common region of homozygosity on chromo-
some 12q24.1 [227,229]. The point mutation was an intronic G to C
transversion (7044G-C) in the ISCU gene, which strengthened a weak
splice acceptor site and resulted in the retention of a 100 base pair (bp)
fragment of intron 5 in the mature mRNA. The aberrantly spliced ISCU
mRNA encoded the wrong C-terminal sequence, which ends with apremature stop codon, leading to translation of a truncated protein with
a markedly reduced half-life [230]. Given the role of ISCU as the primary
scaffold for Fe–S cluster biogenesis, the mutation leads to adverse effects
on Fe–S protein biogenesis and intracellular iron homeostasis. In ﬁfteen
affected members from nine families [222,223], the samemutation in in-
tron 5 of ISCUwas independently identiﬁed [229]. Two brotherswithmy-
opathy, lactic acidosis and cardiac involvement who exhibited a more
severe phenotype than other reported patients were found to be com-
pound heterozygotes for the common intronic mutation (7044G-C) and
for a c.149GNA missense mutation in exon 3 of the second ISCU allele,
changing a highly conserved glycine residue into glutamate (G50E)
[231]. A recent biochemical characterization of ISCUG50E highlighted that
the mutation interferes with the ability of the scaffold protein to interact
with the sulfur donor NFS1 and with the cochaperone HSC20, thus dras-
tically impairing the rate of Fe–S cluster synthesis [232]. Lack of ISCU in
muscle tissue from ISCUmyopathy patients elicits activation of a systemic
metabolic response leading to increased plasma levels of the starvation
response hormone FGF21 (ﬁbroblast growth factor 21) [233]. Interesting-
ly, the incorrect splicing of the ISCUmRNA ismore pronounced inmuscle
than in other tissues, resulting in amuscle-speciﬁc phenotype. Moreover,
the differentiation level of muscle ﬁbers was shown to enhance aberrant
splicing of ISCU, as the muscle-speciﬁc transcription factor MyoD1 de-
creased the amount of normal ISCU transcript in patient myoblasts
[233]. Several studies were carried out to understand the molecular
mechanisms that may contribute to the tissue speciﬁc phenotype of the
disease, and ﬁve nuclear factors were found to interactwith the sequence
harboring the mutation [234], including three splicing factors, SFRS14,
RBM39, and PTBP1, and two additional RNA binding factors, matrin 3
(MATR3) and IGF2BP1. IGF2BP1 showed a preference for the mutant se-
quence, whereas the other factors had similar afﬁnity for both sequences.
PTBP1 was found to repress the defective splicing of ISCU, whereas
IGF2BP1 and RBM39 shifted the splicing ratio toward the incorrect form.
Differential expression of these factors in a tissue speciﬁc manner could
explain the severity of the phenotype in the skeletal muscle of ISCU my-
opathy patients.
A ﬁrst report in 2009 demonstrated the ability of an antisense ol-
igonucleotide (AO), which speciﬁcally targeted the activated cryp-
tic splice sites in the ISCU gene, to restore the correct reading
frame in cultured ﬁbroblasts derived from patients with the homo-
zygous mutation. The restoration was stable, with the correctly
spliced mRNA remaining the dominant species after 21 days [235].
More recently two different antisense oligonucleotides were tested
for their ability to correct the aberrant splicing in muscle-derived
primary cells from ISCU myopathy patients. The oligonucleotides
were based on the phosphorothioate chemistry and they targeted
the splice acceptor or splice donor site of the disease-associated
pseudoexon [236]. Opposite effects were observed with the two
AOs, as the acceptor site antisense oligonucleotide effectively
redirected splicing toward the normal transcript in cultured muscle
ﬁbroblasts, whereas the donor site oligonucleotide promoted intron
inclusion in both patient and control cells. Since only a shift in bal-
ance between abnormal and normal splice variants, and not com-
plete normalization of splicing, seems to be necessary to alleviate
the biochemical defects in HML, the AO treatment appears to be a
promising therapeutic strategy in the ISCU myopathy. However, it
highlights the importance of optimizing the sites targeted by the
antisense oligonucleotides to ensure that proper pre-mRNA splicing
takes place.
5.5. Mitochondrial encephalopathy with deﬁciency in NUBPL (IND1) (MIM
613621)
Deﬁciency of respiratory chain complex I (NADH: ubiquinone oxido-
reductase) is themost common causative factor underlyingmitochondri-
al disorders, accounting for approximately a third of all cases of OXPHOS
disorders [100,237]. Complex I is the largest enzyme of the
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structure was initially revealed by electron microscopy. X-ray crys-
tallographic studies of the complexes isolated from Thermus
thermophilus, Y. lipolitica, and E. coli subsequently provided further
structural details [238–242]. Ongoing efforts have been made to
determine the position of the different subunits in the mamma-
lian enzyme by crystallizing puriﬁed complex I from bovine
heart. Human complex I is very similar to the bovine complex
and consists of 45 different subunits [243], 14 of which consti-
tute the core catalytic subunits and are conserved in all species
that have complex I, including prokaryotes [244]. Seven of
these core subunits are hydrophobic and mitochondrially
encoded, and the other seven are hydrophilic and encoded by
the nuclear genome. The remaining 31 subunits are often re-
ferred to as accessory or supernumerary subunits. Central to
complex I enzymatic activity is a chain of eight Fe–S clusters in
the peripheral arm that facilitates transfer of single electrons from
NADH to ubiquinone. The energy generated by the electron transfer is
transduced to the membrane arm, which then pumps protons into the
intermembrane space to generate the electrochemical gradient utilized
for ATP synthesis [240]. Sequencing of the known 45 genes encoding
structural subunits of complex I offered a genetic explanation for
about 50% of affected individuals [146], thus suggesting that additional
factors that are not integral to the mature complex are required for ef-
fective complex I assembly and function [100,245,246]. Ind1 has been
identiﬁed and characterized as an assembly factor for complex I in the
model organism Y. lipolitica [144]. Ind1 was proposed to be essential
for the assembly of Fe–S clusters for complex I on the basis of several ob-
servations: it has sequence similarities to Nbp35 and Cfd1, which are
scaffold proteins for cytosolic Fe–S cluster biogenesis, it is targeted to
mitochondria and is able to bind a labile Fe–S cluster in vitro, and its
knock down had adverse effects on complex I activity and assembly
[144]. The human ortholog, NUBPL (nucleotide-binding protein-like
protein) or IND1, was similarly proposed to be crucial for delivery of
Fe–S clusters to complex I [145]. However, recent studies in A. thaliana
demonstrated a primary role of IND1 (INDH) in mitochondrial transla-
tion, which secondarily affects complex I assembly because seven of its
core subunits are mitochondrially encoded [147]. Nevertheless, NUBPL
mutations are known to cause defects in complex I activity and assem-
bly associated with mitochondrial encephalopathy [146,247]. The
c.815-27TNC branch-site mutation in NUBPL affects mRNA splicing
[146,248], and it was identiﬁed in seven unrelated individuals with mi-
tochondrial syndromes. High-throughput screen of a cohort of 103 pa-
tients with complex I deﬁciency led to identiﬁcation of a second
missense mutation in exon 2 in the NUBPL gene [146], c.166GNA,
which causes the substitution of Gly56 into Arg [248]. Most of the pa-
tients are compound heterozygotes with one null allele and the other
carrying the branch-site mutation (c.815-27TNC) in combination with
a c.166GNA missense mutation [249,250]. All the patients exhibit a
characteristic leukoencephalopathic pattern on brain MRI, conﬂuent
or multifocal cerebral white matter lesions, along with abnormalities
and swelling of the corpus callosum. Moreover, patients developed
motor problems due to ataxia in the ﬁrst years of life, whereas
other features were more variable, as some patients showed contin-
uous regression whereas others manifested only episodic regression
with differences in cognitive capabilities ranging from normal to sig-
niﬁcantly deﬁcient. In a German patient, two mutations were identi-
ﬁed in the NUBPL gene [250]: a 10-bp insertion in exon 8 on one
allele, resulting in premature termination (Glu223AlafsTer4) and
the combination of c.166GNA/c.815-27TNC on the other allele. Differ-
ent missense mutations in NUBPL (D105Y, L193F) were also found in
two Canadian siblings and in a patient from the Netherlands, in com-
bination with c.166GNA/c.815-27TNC [250]. Finally, a G to A transi-
tion in intron 8, predicted to cause skipping of exon 8 was
identiﬁed in an American patient, who harbored the c.166GNA/
c.815-27TNC mutations on the second allele [250].5.6. Mitochondrial muscle myopathy with deﬁciency of ferredoxin 2
(FDX1L)
The human genome contains two homologous ferredoxins, FDX1,
located on chromosome 11q22 and highly expressed in adrenal cor-
tex and medulla, and the ubiquitous FDX1L, renamed FDX2, on chro-
mosome 19p13.2 [63]. Both FDXs are involved in Fe–S cluster
biogenesis, together with ferredoxin reductase (FDXR), providing
reducing equivalents [32]. FDX1 was also found to be essential for
the synthesis of various steroid hormones in adrenal glands [63].
FDX1L encodes a 183 amino acid [Fe2–S2] mitochondrial protein. A
homozygous mutation c.1ANT was recently identiﬁed in the FDX1L
gene, which disrupts the ATG initiation translation site, resulting in
severe reduction of FDX2 levels in the patient muscle and ﬁbroblasts
mitochondria [251]. The patient presented with an adolescent onset
proximal muscle myopathy associated with recurrent episodes of
myoglobinuria and lactic acidosis. The biochemical features of the
disease included severe reductions in the activities of mitochondrial
aconitase (25% of normal) and of the Fe–S dependent respiratory
chain complexes I to III in the patient's skeletal muscle (6–36% of
normal), with complex II being the most severely affected, whereas
citrate synthase activity was normal, consistent with the crucial
role of FDX2 as a core component of the Fe–S cluster assembly ma-
chinery. Elevated lactate, ketones and Krebs cycle metabolites de-
tected in the urine, together with low pyruvate dehydrogenase
complex (PDHc) activity in muscle homogenate were indicative of
a generalized metabolic remodeling caused by impaired Fe–S cluster
biogenesis for several mitochondrial enzymes, including lipoic acid
synthase.
5.7. Lipoic acid defects due to mutations in Fe–S cluster biogenesis compo-
nents (NFU1, BOLA3, IBA57, and GLRX5)
Lipoic acid (LA) is a covalently bound cofactor essential forﬁve redox
reactions in humans: in four 2-oxoacid dehydrogenases and in the gly-
cine cleavage system (GCS) (reviewed in [252]). Two enzymes are es-
sential for energy metabolism (α-ketoglutarate dehydrogenase α-
KGDH, and pyruvate dehydrogenase PDH), and three are involved in
amino acid metabolism pathways (branched-chain ketoacid dehydro-
genase BCKDH, 2-oxoadipate dehydrogenase, and the GCS). LA synthe-
sis has been extensively investigated in S. cerevisiae [253], and for most
but not all of the involved enzymatic reactions, orthologues have been
identiﬁed in humans. LA is synthesized inmitochondria by a series of re-
actions involving transfer of an octanoyl group to a ﬁrst acceptor protein
(H protein of the GCS), lipoate synthesis by insertion of two sulfhydryl
groups into the side chain of the bound octanoic acid, and ﬁnal transfer
of newly synthesized lipoate from the H protein to the E2 subunits of 2-
oxoacid dehydrogenases. The octanoyl moiety attached to a conserved
lysine of the H protein of the GCS [254] is converted into lipoate by
sulfurylation at positions 6 and 8 catalyzed by the radical S-
adenosylmethionine (SAM) enzyme lipoic acid synthase (LIAS) [255].
LIAS has two [Fe4–S4] clusters, which are essential for the enzymatic re-
action as one of them provides sulfur for sulfurylation of octanoate to
lipoate, during catalysis [252]. Lipoic acid defects were found in four
syndromes caused by mutations in NFU1 (MMDS1, multiple mitochon-
drial dysfunctions syndrome 1 [133,135,136]), BOLA3 (MMDS2, multi-
ple mitochondrial dysfunctions syndrome 2 [133,134,256]), IBA57
(MMDS3, multiple mitochondrial dysfunctions syndrome 3 [36]), and
GLRX5 (non ketotic hyperglycinemia [256]). Clinical features of individ-
uals affected by the multiple mitochondrial dysfunctions syndromes,
which is often fatal at perinatal stages, include hypotonia, respiratory
insufﬁciency, encephalopathy, myopathy, brainmalformation, and neu-
rological regression. Patients have metabolic acidosis with elevated
blood lactate levels, hyperglycinemia, compromised mitochondrial res-
piration, and reduced activities of the lipoic acid dependent enzymes
PDH, α-KGDH, BCKDH and GCS.
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by mutations in NFU1 (MIM# 605711)
Initially reported in 2001 by Seyda et al. in three siblings of Mexican
origins [257], MMDS1 is a severe autosomal recessive disorder of
systemic energy metabolism, resulting in weakness, respiratory fail-
ure, lack of neurologic development, lactic acidosis and early death.
The underlying genetic defect of MMDS1 was later identiﬁed by
Cameron et al. [133] in the NFU1 gene: a homozygous missense mu-
tation c.545GNA near the splice donor site of exon 6 caused aberrant
splicing of NFU1 mRNA and no mature protein could be detected in
ﬁbroblasts from the patients. Biochemical analysis revealed severe
deﬁciencies of pyruvate dehydrogenase complex (PDHc) and α-
ketoglutarate dehydrogenase complex (α-KGDH), due to reduced
lipoylation of the E2 subunits of these enzymes, and decreased activ-
ities of respiratory chain complexes I, II and III, whereas aconitase ac-
tivity was normal. High glycine, leucine, valine and isoleucine levels
were detected in the urine samples from the patients indicating ab-
normalities of the GCS and branched-chain α-ketoacid dehydroge-
nase, both of which depend on covalently attached lipoate. In 9
patients from unrelated Spanish families with fatal infantile enceph-
alopathy, hyperglycinemia, pulmonary hypertension, lactic acidosis
and impaired PDHc activity, Navarro-Sastre et al. [135] identiﬁed a
homozygousmutation in the NFU1 gene, causing the missensemuta-
tion G208C, which was shown to impair NFU1 function. MMDS1 re-
sults from compromised biogenesis of LIAS, which has been
proposed to acquire its Fe–S clusters from NFU1.
5.9. Multiple mitochondrial dysfunctions syndrome 2 (MMDS2) is caused
by mutations in BOLA3 (MIM# 614299)
The clinical and biochemical phenotypes ofMMDS2 caused bymuta-
tions in BOLA3 closely resemble the condition determined by NFU1 de-
ﬁciency, with a severe epileptic encephalopathy and dilated
cardiomyopathy, elevated lactate and glycine levels, reducedmitochon-
drial respiration and low PDH,α-KGDH and GCS activities reported in at
least six patients identiﬁed so far [133,134,256,257]. Three different
types of missense mutations in BOLA3 were found to be responsible
for the disease: a homozygous single base pair duplication
(c.123dupA) leading to a frameshift and a premature stop codon
(p.Glu42Argfs*13) [133], a c.136CNT point mutation in exon 2 of the
BOLA3 gene producing a truncated protein (p.R46* stop codon) [256],
causing the less severe phenotype reported, and a homozygous muta-
tion on exon 3 of the BOLA3 gene, resulting in the substitution of Ile67
into Asn [134]. Because of the similar phenotypes of MMDS1 and
MMDS2, BOLA3 has been proposed to function in concert with NFU1
for biogenesis of LIAS [133]. However, this hypothesis needs to be sup-
ported by further experimental evidence.
5.10. Multiple mitochondrial dysfunctions syndrome 3 (MMDS3) is caused
by mutations in IBA57 (MIM# 615330)
Bolar et al. [36] reported the case of two siblings, born from consan-
guineousMoroccan parents, with a lethal encephalomyopathy andmy-
opathy resulting from mitochondrial dysfunction. Laboratory studies
showed severe lactic acidosis and increased glycine in cerebrospinal
ﬂuid (CSF). Both infants died soon after birth. The severe phenotype
was caused by a homozygous missense mutation in the IBA57 gene,
resulting in a Gln314Pro substitution in a non conserved region of the
protein. Biochemical characterization of IBA57Q314P in HeLa cells
showed that the missense mutation diminished the activity of IBA57,
and the mutant protein was particularly prone to proteolytic degrada-
tion. Although the exact molecular function of IBA57 is not known, ex-
perimental evidences obtained in cell lines and in the patients have
suggested that it is involved in the biogenesis of [Fe4–S4] mitochondrial
proteins [36,143].5.11.Mutations in GLRX5 cause sideroblastic anemia or variant non-ketotic
hyperglycinemia
A homozygous 294ANG transition in the third nucleotide of the last
codon of GLRX5 exon 1 genewas identiﬁed in 2007 in a southern Italian
man with autosomal recessive pyridoxine-refractory siderobastic ane-
mia [109]. Themutationwas shown by RT-PCR to interfere with correct
splicing. Sideroblastic anemias (SAs) are a group of heterogeneous con-
genital and acquired disorders that have common features ofmitochon-
drial iron accumulation in bone marrow erythroid precursors (ringed
sideroblasts), ineffective erythropoiesis, increased levels of tissue iron
and varying amounts of hypochromic erythrocytes in the peripheral
blood [258,259]. Congenital sideroblastic anemia is a rare disease
caused bymutations of genes involved in heme biosynthesis, Fe–S clus-
ter biogenesis, andmitochondrial protein synthesis (Pearson's marrow-
pancreas syndrome or PMPS). The most common form is the X-linked
sideroblastic anemia, caused by mutations in the erythroid-speciﬁc δ-
aminolevulinate synthase (ALAS2), the ﬁrst enzyme of the heme bio-
synthetic pathway in erythroid cells [259,260]. The human genomecon-
tains two ALAS genes: the ALAS2 transcript has an IRE in its 5′-UTR and is
speciﬁcally expressed in erythroid cells, whereas the ALAS1 transcript
lacks an IRE and is ubiquitously expressed. Other mutations known
to cause sideroblastic anemias are mitochondrial DNA deletions
[261], or mutations in the erythroid speciﬁc mitochondrial trans-
porter (SLC25A38) [262], the adenosine triphosphate (ATP) binding
cassette B7 (ABCB7) [263], the thiamine transporter SLC19A2 [264],
the tRNA-modifying enzyme pseudouridine synthase (PUS1) [265],
themitochondrial tyrosyl-tRNA synthase (YARS2) [266], and the gly-
cyl-tRNA synthetase (GARS) [267]. An animal model for studies of SA
caused by loss of glutaredoxin 5 is zebraﬁsh shiraz, a pale mutant in
which blood cells are severely hypochromic, deﬁnitive hematopoie-
sis is defective, and the condition is lethal between day 7 and 10 after
fertilization [103]. The shiraz phenotype is caused by a large deletion
encompassing the GLRX5 gene. Loss of GLRX5 compromises Fe–S
cluster biogenesis, and causes activation of IRE binding activity of
IRP1 (IRP2 was found not to have a role in shiraz), which ultimately
leads to anemia due to IRP-mediated inhibition of ALAS2 translation
[103]. Loss of its Fe–S cluster converts IRP1 from cytosolic aconitase
(ACO1) into the IRE-binding form. IREs are present in either the 5′
or 3′ terminal UTR of several gene transcripts, most of which encode
proteins involved in ironmetabolism, that are respectively repressed or
stabilized by IRP1 binding. The transcript of ALAS2, which catalyzes the
ﬁrst step of heme synthesis in mitochondria of erythroblasts, contains a
5′-IRE, and its translation is repressed by IRP1 binding. Ferrochelatase
contains a labile [Fe2–S2] cluster that is required for its function and sta-
bility [268]. Therefore, activities of the ﬁrst and last steps of heme bio-
synthesis in erythroid cells are governed by the Fe–S cluster
biogenesis status in cells, either by determining activity of IRP1 or by di-
rectly contributing to activity/stability of a Fe–S enzyme [108]. Overex-
pression of ALAS2without the 5′-IRE rescued shiraz embryos, as also did
knockdown of IRP1, whereas overexpression of the 5′-IRE isoform of
ALAS2 did not [103]. The GLRX5 patient was an anemic middle-aged
manwhen he started developing severe symptoms, includingmicrocyt-
ic hypochromic anemia, type II diabetes, cirrhosis, and liver iron over-
load [109]. Patient cells showed decreased GLRX5 expression, low
levels of H-ferritin and ferrochelatase and high TfR, consistent with ac-
tivation of IRE-binding activity of IRP1. Loss of GLRX5 resulted in mito-
chondrial iron overload and concomitant cytosolic iron depletion with
subsequent stabilization of IRP2, which started a vicious cycle enhanc-
ing repression of ferritin and ALAS2 in erythroblasts and increasing mi-
tochondrial iron [108]. Anemiawas partially reversed by iron chelation,
perhaps by promoting a redistribution of iron to the cytosol, which
might lead to IRP2 degradation, thus improving heme synthesis and
anemia [109]. The phenotypes caused by loss of GLRX5 underscore
the causal link between Fe–S cluster biogenesis and heme synthesis,
with IRP1 being a major player in the process [12,13,269,270].
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three individuals harboring different mutations in the GLRX5 gene
[256], two of whom shared a Lebanese origin and a homozygous dele-
tion c.151_153delAAG (p.K51del) in GLRX5 exon 1. The third patient
of Chinese descent had the same deletion on the maternal allele and
an 8 bp insertion c.82_83insGCGTGCGC (p.G28Gfs*25), resulting in a
premature stop codon at amino acid 52, 25 amino acids downstream,
on the paternal allele. The deleted Lys51 is highly conserved from
human toC. elegans, and is predicted to be deleterious in silico. It is locat-
ed on the surface, between the ﬁrst α-helix and the ﬁrst β-sheet of
GLRX5, and it's close to K59, which interacts directly with the Fe–S clus-
ter at the active site [256]. The patients were diagnosedwith non-ketot-
ic hyperglycinemia characterized by speciﬁc deﬁciencies in lipoate
metabolism, pointing to improper biogenesis of LIAS. Glycine accumu-
lates in blood and brain due to compromised activity of the GCS and
contributes to the neurodegenerative phenotype [271]. Interestingly,
no defect in Fe–S enzymes other than LIAS has been identiﬁed in any
of the three patients, iron metabolism was found to be normal, and
their phenotype was completely different from the patient affected by
SA, who conversely did not show any neurological symptoms.
5.12. X-linked sideroblastic anemia with cerebellar ataxia (XLSA/A) due to
mutations in ABCB7
First isolated in 1997 from amurinemacrophage cDNA library [272],
theATP-binding cassette (ABC) transporter ABCB7wasmapped to the X
chromosome both inmice and humans [272]. Mutations in ABCB7 cause
X-linked sideroblastic anemia with cerebellar ataxia (XLSA/A), a reces-
sive disorder characterized by an infantile to early childhood onset of
non-progressive cerebellar ataxia and mild anemia with hypochromia
andmicrocytosis. A distinguishing feature of the disease is the presence
of iron-loadedmitochondria (sideroblasts), and defects in hememetab-
olism with protoporphyrin IX accumulation [273–275]. Defects in
ABCB7 have also been proposed to mediate ineffective erythropoiesis
in refractory anemia with ring sideroblasts (RARS) [276,277], a
myelodysplastic syndrome (MDS) characterized bymitochondrial ferri-
tin (FTMT) accumulation, and in the refractory anemia with ring
sideroblasts and isodicentric (X) (q13) chromosome [278]. It seems
that the anemia and the ataxia observed in XLSA/A are related to altered
iron homeostasis which leads tomitochondrial iron accumulation in de-
veloping red blood cells and in neural cells [279,280].
ABCB7 is the human ortholog of yeast Atm1. Atm1 has been recently
crystallized in its nucleotide-free and glutathione-bound form [281],
and it localizes to the innermitochondrialmembrane [282]with the nu-
cleotide binding domain (NBD) facing thematrix: therefore it is thought
to function as an exporter. Upon Atm1 depletion, mitochondria accu-
mulate iron [153,154,283,284]. Depletion of ABCB7 orthologs in plants,
mice and HeLa cells results in loss of cytosolic aconitase activity, mito-
chondrial iron accumulation and increased sensitivity to oxidative
stress, whereas no signiﬁcant changes in activities of mitochondrial
Fe–S enzymes (i.e. ACO2 or SDH) have been reported [153,154,280,
285,286]. It has been proposed that Atm1 exports a sulfur-containing
compound necessary for biogenesis of Fe–S clusters in the cytosol
[107,153,156]. However this hypothesis has been recently questioned
because genetic manipulations, which were carried out to inactivate
ATM1, also introduced LEU2 into a LEU2-null strain (ΔLEU2), which un-
expectedly led to transcriptional repression of LEU1 relative to the con-
trol strain [287]. Leu1 is the isopropylmalate isomerase, a cytosolic Fe–S
protein that has been used to assess cytosolic Fe–S cluster biogenesis.
Because Leu1 activity was low in Atm1 null strains, this was
misinterpreted as evidence that Atm1 contributed to export of a compo-
nent essential to cytosolic Fe–S cluster biogenesis [287]. Loss of Atm1
can be partially compensated by the overexpression of an Atm1 homo-
logue, Mdl1, which exports peptides derived from the degradation of
mitochondrial inner membrane proteins to the intermembrane space
and cytosol [288,289]. Orthologs of yeast Atm1 are found in virtuallyall eukaryotes and some bacteria [290], and the ABC transporter ATM3
in A. thaliana, which can functionally complement a yeast ΔATM1 strain
[291], was found to be essential for the export of the cyclic pyranopterin
monophosphate (cPMP) intermediate frommitochondria to the cytosol
for the biogenesis of the molybdenum cofactor [292]. It has been there-
fore proposed that ATM3 transports two distinct compounds or a single
molecule required for both Fe–S and molybdenum cofactor biogenesis
in the cytosol [285]. Interestingly, neither ATM1 nor ATM3 null strains
are lethal, suggesting that there might be some redundancy between
different ABC transporters. Atm1 binds glutathione (GSH) with high af-
ﬁnity during the puriﬁcation steps carried out in E. coli [281]. GSH stim-
ulates the ATPase activity of Atm1, and Atm1- deﬁcient mitochondria
accumulate glutathione in vivo [286,293]. However, GSH itself cannot
be the physiological substrate because it is synthesized in the cytosol,
where the main cellular pool resides, though it could be part of the
exported moiety [281]. Interestingly, all the residues that coordinate
GSH were found to be conserved in Atm1-like proteins, including
human ABCB7 and the bacterial orthologs [281]. One of these residues,
D398, corresponds to E433 on the human ABCB7, and it is mutated
into lysine in patientswith XLSA/A, showing the physiological relevance
of the substrate-binding pocket of the transporter [274]. Three of the
XLSA/A patient mutations are located in the membrane domain either
on the matrix [294] or the intermembrane space sides [273–275], and
they are highly conserved, suggesting their critical importance for
ABCB7 function [281].
5.13. Variant erythropoietic protoporphyria caused by abnormal
expression of mitoferrin 1
Erythropoietic protoporphyria (EPP) is an inbornmetabolic disorder
characterized by accumulation of protoporphyrin in red cells and in
the skin, where it causes photosensitivity [295–297]. The most se-
vere clinical feature is hepatobiliary disease due to protoporphyrin-
induced damage to liver cells [298]. Deﬁciency of the Fe–S enzyme
ferrochelatase (FECH), which catalyzes the insertion of ferrous iron
into protoporphyrin to form heme, is the most common cause of
EPP [299–301]. A variant form of EPP has been linked to aberrant
splicing ofMFRN1mRNA, which encodes the erythroblastic speciﬁc sol-
ute carrier mitoferrin 1 (MFRN1, SLC25A37), the major importer of iron
into mitochondria in erythroblastic cells [302]. MFRN1 has a paralog,
MFRN2, which is mostly expressed in non-erythroid cells [303]. Fine
regulation of iron import into mitochondria is essential for heme bio-
synthesis, hemoglobin production and Fe–S cluster biogenesis during
red cell development. Shaw et al. described a zebraﬁsh mutant, frascati
(frs), that had profound hypochromic anemia and erythroidmaturation
arrest due to defects in mitochondrial iron uptake [302]. Through posi-
tional cloning, they found that the genemutated in the frsmutantwas a
member of the vertebrate mitochondrial solute carrier family (SLC25)
which was named mitoferrin (mfrn). Mitoferrin 1 is highly expressed
in fetal and adult hematopoietic tissues of zebraﬁsh and mouse. Eryth-
roblasts generated from murine embryonic stem cells null for Mfrn
showed maturation arrest with severely impaired incorporation of
55Fe into heme. Disruption of the yeast mfrn orthologs, MRS3 and
MRS4, caused defects in iron metabolism and in mitochondrial Fe–S
cluster biogenesis [304–306]. MFRN1 was found to be part of an oligo-
meric complex containing also FECH and ABCB10, which was proposed
to integrate mitochondrial iron import with heme synthesis [307].
Therefore, defective MFRN1 could decrease transport of iron to FECH,
or impair formation of the [Fe2–S2] cluster essential for human FECH ac-
tivity [308], and for the stability of the protein [268]. Six out of seven pa-
tients affected by EPP were found to have an insertion of a 477 bp
segment in theMFRN1 gene, due to activation of a cryptic donor splice
site (GT) in intron 2, which causes a nonsense codon (TAG) at amino
acid 156 [309]. Importantly, ﬁve of the affected individuals harbored
also defects in the genes of ferrochelatase and ALAS2, which complicates
the interpretation of the phenotype associated with accumulation of
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mia, but mutant animals do not show signs of protoporphyria. The
mechanism that prevents protorphyria inMFRN1 knock out animals re-
lies on the regulatory role played by IRP1. IRP1 attenuates protoporphy-
rin biosynthesis by binding to the 5′ IRE of ALAS2mRNA, inhibiting its
translation and preventing protoporphyrin accumulation. IRP1 deﬁ-
ciency or ectopic expression of ALAS2 harboring a mutated IRE that
can't bind IRP1 is responsible for protoporphyria [310]. In patients
with EPP, mis-splicing of MFRN1 mRNA is particularly frequent, al-
though the underlying mechanism has not been determined. The ma-
jority of these mRNAs are degraded by nonsense-mediated decay,
whereas the remaining transcripts encode a truncated protein that is
not properly targeted tomitochondria. The net result is a signiﬁcant de-
crease in the amount of functional MFRN1, which is in turn responsible
for reduced import of iron into mitochondria with adverse effects on
Fe–S cluster biogenesis and heme synthesis.
6. Mitochondrial iron homeostasis and Fe–S cluster biogenesis
It is known that defects in the basic pathway of Fe–S cluster bio-
genesis lead to mitochondrial iron overload and cytosolic iron deple-
tion in mammalian cells [30,31,311]. The regulatory mechanisms of
this crucial pathway are different in yeast and mammals, but a dy-
namic, ﬁne balance between mitochondrial iron requirements for
Fe–S cluster biogenesis, heme synthesis and cellular iron regulation
appears to be a key signal that supports normal homeostasis. In
yeast, iron uptake and intracellular distribution mainly rely on a
transcriptional regulatory mechanism that involves Aft1 and Aft2
[312], two transcriptional factors which translocate to the nucleus
under low iron conditions to activate genes of the iron regulon to
control iron uptake and intracellular distribution. Yeast strains har-
boring deletions of the cysteine desulfurase Nfs1 have a N30-fold in-
crease in mitochondrial iron levels compared to wild type strains
[153,313]. Similarly, depletion of components of the Fe–S cluster bio-
genesis machinery, such as Yfh1 [314], Isu1, Isu2 [315,316], Nfu1,
Isa1, Isa2 [139], Ssq1 [317], Jac1 [90], Yah1 [318] impairs Fe–S bio-
genesis and causes mitochondrial iron overload [319], in the form
of iron (III) phosphate nanoparticles [320,321]. Aft1 activates genes
of the iron regulon in yeast strains with mutations in Nfs1 and Ssq1
[313], perhaps by responding to a signal from an Fe–S protein or to
the altered mitochondrial utilization of iron for the biogenesis of
Fe–S clusters [322,323]. In mammalian cells, mitochondrial iron
overload occurs concomitantly with cytosolic iron depletion as
judged by activation of IRPs [50,68,210], and it is a characteristic fea-
ture of the heart and neurons of FRDA patients [324], the skeletal
muscle of individuals with ISCU myopathy [227], the precursors of
red blood cells in a patient with SA caused by deﬁciency of GLRX5
[108], and in individuals affected by X-linked sideroblastic anemia
and ataxia caused by mutations in ABCB7 [273]. Both in yeast and
in humans, mitochondrial iron overload can be readily reversed by
restoration of the missing Fe–S cluster biogenesis protein. Several
hypotheses have been proposed to explain the intimate connection
between Fe–S cluster biogenesis and iron homeostasis. It has been
suggested that iron accumulates in mitochondria when Fe–S cluster
biogenesis is compromised because it cannot be incorporated into
Fe–S clusters destined to ligate to mitochondrial proteins or to be
exported in the form of a precursor in order to support cytosolic
Fe–S cluster biogenesis [153]. Later on, this hypothesis was
dismissed, as it was suggested that ABCB7 (Atm1 in yeast) exports
a sulfur-containing compound, which no longer provides an expla-
nation for mitochondrial iron overload [107,156]. One possibility
could be that an Fe–S protein is directly or indirectly involved in
the sensing of iron levels in mitochondria, so that compromised
Fe–S biogenesis might be registered as insufﬁcient provision of iron
to the mitochondrial compartment. This could result in a feedback
regulation and activation of a response that includes the increaseddelivery of iron to mitochondria and concomitant depletion of the
cytosolic iron pool, which ﬁnally engages the cell in a vicious cycle
in which increased cellular iron uptake further exacerbates mito-
chondrial iron overload [313,325]. In support of this idea, transcrip-
tional expression of the mitochondrial iron importer mitoferrin is
increased in frataxin-deﬁcient mouse hearts [211], and in muscle bi-
opsies from the ISCUmyopathy patients [233]. An attractive possibil-
ity is that a molecule exported from mitochondria acts as a signal
that drives iron import. Active export of peptides from themitochon-
drial matrix to the intermembrane space in S. cerevisiae is accom-
plished by the ABC transporter Mdl1, which was proposed to be
crucial for yet-to-be-determined signal transduction pathways in
yeast [288]. Several cellular pathways, such as the stress of protein
misfolding in the mitochondrial matrix, have been dissected, and
they were found to rely on export of signaling molecules, which ac-
tivate nuclear-encoded mitochondrial genes [326–328]. Mdl1 is ho-
mologous to Atm1 and it can partially compensate for ATM1 loss
when overexpressed. The Atm1/ABCB7 substrate is so far unknown.
It might be interesting to investigate the nature of the molecule
that is exported by Atm1/ABCB7, as this could help the understand-
ing of the regulatory networks that are key to the control of mito-
chondrial iron homeostasis.Acknowledgements
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